1. BASKET-PROVE II
Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer everolimus-eluting stent (n=765) vs. a durable-polymer everolimus-eluting stent (n=765) vs. a bare-metal stent (n=761).
Results
(p = for noninferiority for biodegradable vs. durable)
(p = for superiority for biodegradable vs. bare-metal stent)
CV death, MI, or TVR at 2 years: 7.6% with biodegradable-polymer vs. 6.8% with durable-polymer vs. 12.7% with bare-metal stent (p = for noninferiority; biodegradable-polymer vs. durable-polymer, p = for superiority; biodegradable-polymer vs. bare-metal stent)
CV death, MI, or definite/probable stent thrombosis at 2 years: 3.7% with biodegradable-polymer vs. 3.8% with durable-polymer vs. 5.0% with bare-metal stent
12.7 %
7.6
6.8
Conclusions
Among patients with stable or unstable coronary artery disease, a biodegradable-polymer drug-eluting stent was noninferior to a durable-polymer drug-eluting stent and superior to a bare-metal stent with regard to efficacy
Similar safety profile
Biodegradable-polymer drug-eluting stent
Durable-polymer drug-eluting stent
Bare-metal stent
Kaiser C, et al. Circulation 2014;Nov 14:[Epub]